Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus paracasei GM080
- Development stage
- Unknown
- Lead developer
- GenMont Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus paracasei GM080 (reclassified as Lacticaseibacillus paracasei GM-080) is a probiotic strain developed by GenMont Biotech Inc. for the treatment of allergic diseases. Originally isolated from the human gastrointestinal tract and deposited under accession number CCTCC M 204012, the strain is investigated in both live and heat-treated forms. Its primary mechanism of action involves the modulation of the host immune system, specifically by inducing the secretion of Th1-type cytokines such as interferon-gamma (IFN-γ) and interleukin-12 (IL-12). This shift in the Th1/Th2 balance makes it a candidate for managing atopic dermatitis and allergic rhinitis. Clinical evaluation has been supported by GenMont and partners like Société des Produits Nestlé.
- Brand names
- AAP-1AAP1AAP 1LP33LP-33LP 33
- Other names
- Lacticaseibacillus paracasei GM-080Lactobacillus paracasei GM-080
02
Targets
IL12 (Interleukin-12)IFNG (Interferon gamma)
Beyond the preview
Go deeper on lactobacillus paracasei GM080.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus paracasei GM080.